Skip to main content
  • Register Today

    Learn more about meeting registration.

    In conjunction with the American Society of Ophthalmic Plastic and Reconstructive Surgery

    Oculofacial Plastic Surgery 2024: Different Insights in Oculofacial Plastic Surgery Focusing on the Nuances

    Dive into the diagnosis and management of oculofacial plastic surgery including orbit, eyelid, and lacrimal conditions.

    Saturday, Oct. 19
    McCormick Place, Chicago, Illinois

    Breakfast will be served for in-person attendees at 7 a.m. Pacific Daylight Time. The program will start at 8 a.m. Pacific Daylight Time.

    Program Directors

    Steven M. Couch, MD, FACS
    Eric A. Steel, MD

    Program Planning Group

    Steven M. Couch, MD, FACS
    Eric A. Steel, MD


    View the schedule in the AAO 2024 Meeting Guide. Click the Program button on the homepage, then select Program Search. Choose among the Subspecialty Day meeting options under the "Filter by Meeting" drop-down menu. You can select multiple filters/meetings.

    Mission Statement

    The mission of the 2024 Oculofacial Plastic Surgery Subspecialty Day is to update surgeons on the latest trends in in oculofacial plastic and reconstructive surgery. 

    Target Audience

    The intended audience is oculofacial plastic surgeons and comprehensive ophthalmologists of all levels performing basic or complex orbit, eyelid, and/or lacrimal surgery, as well as physicians in training. 

    Education Level

    Basic, Intermediate, Advanced 

    Program Objectives

    Upon completion of this activity, participants should be able to:

    • Improve the quality and safety of surgeries of the orbit, eyelid, and lacrimal system, and be familiar with the various standard and high-tech modalities available.

    • Distinguish preferences in nonsurgical and surgical aesthetic facial rejuvenation.

    • Describe pitfalls in the treatment of challenging conditions or patients.

    • Describe the currently available drugs for thyroid eye disease and an introduction into the future drugs currently in clinical trials.

    • Discuss updates on corneal neurotization surgery to enhance treatment of the neurotrophic cornea, as well as on trending medications, such as thyroid biologic agents and oxymetazoline.